Back to Atlas
CTransientStandard research/education caution
CMP-0346
Investigational/discontinued
GLPG0492
Ergogenic / SARM
Muscle-disorder research positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- SARM
- Primary mechanism
- Selective androgen receptor agonism
- Primary market use
- Muscle disorders
Pharmacology
- Molecular weight (Da)
- 452.35
- Oral bioavailability
- Oral/preclinical-clinical research
- Half-life
- ~1–12 h provisional PK estimate
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- Preclinical/Clinical
- Clinical status
- Investigational/discontinued
- Value-for-money score
- 3 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Developed for muscle disorders; no approved use